VYNE Therapeutics (NASDAQ:VYNE) Posts Earnings Results, Beats Estimates By $0.03 EPS

VYNE Therapeutics (NASDAQ:VYNE) posted its quarterly earnings data on Thursday. The company reported ($0.28) EPS for the quarter, beating the consensus estimate of ($0.31) by $0.03, Zacks reports. VYNE Therapeutics had a negative return on equity of 43.73% and a negative net margin of 6,896.55%. The firm had revenue of $0.08 million during the quarter, compared to the consensus estimate of $0.14 million.

VYNE Therapeutics Stock Down 6.0 %

Shares of VYNE opened at $2.19 on Friday. VYNE Therapeutics has a 52-week low of $1.57 and a 52-week high of $4.30. The company has a market capitalization of $32.30 million, a PE ratio of -2.55 and a beta of 1.13. The stock has a fifty day simple moving average of $2.76 and a two-hundred day simple moving average of $2.50.

Analyst Upgrades and Downgrades

Several research analysts recently commented on the company. HC Wainwright reissued a “buy” rating and issued a $5.75 price objective on shares of VYNE Therapeutics in a research note on Thursday. BTIG Research assumed coverage on VYNE Therapeutics in a research note on Monday, November 18th. They issued a “buy” rating and a $8.00 price objective for the company.

Insiders Place Their Bets

In related news, Director Patrick G. Lepore bought 15,000 shares of the business’s stock in a transaction on Wednesday, January 15th. The stock was acquired at an average cost of $2.92 per share, with a total value of $43,800.00. Following the purchase, the director now directly owns 51,472 shares of the company’s stock, valued at $150,298.24. The trade was a 41.13 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Corporate insiders own 4.80% of the company’s stock.

VYNE Therapeutics Company Profile

VYNE Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure.